Transdermal composition containing selegiline

Selegilin enthaltendes transdermales Arzneimittel

Composition transdermique à base de sélégiline

Abstract

The invention concerns an anhydrous transdermal preparation comprising in a 20-100% lyotropic liquid crystalline arrangement:    5-15 w.% of optically active or racemic N-methyl-N-(phenyl-2-propyl)-2-propynylamine or N-methyl-N-(1-(4-fluoro-phenyl)-2-propyl)-2-propynylamine or their therapeutically acceptable salts,    40-70 w.% of liquid polyoxyethyleneglycol,    10-20 w.% of solid polyoxyethyleneglycol,    2-30 w.% of a nonionic surface active agent,    2-20 w.% of propyleneglycol, if desired 0.5-2 w.% of a polymer the a value of which is > 0.6, and if desired other auxiliary agents.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    EP-0406488-A1January 09, 1991Somerset Pharmaceuticals, Inc.Pharmazeutische Zubereitung zur Behandlung des Parkinson-, Alzheimer- und depressiven Syndroms
    WO-8909051-A1October 05, 1989Sandoz Ag, Sandoz-Patent-Gmbh, Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H.Deprenyl for systemic transdermal administration

NO-Patent Citations (0)

    Title

Cited By (34)

    Publication numberPublication dateAssigneeTitle
    CN-102188410-ASeptember 21, 2011日东电工株式会社, 藤本株式会社Selegiline-containing adhesive preparation
    DE-19743323-A1April 01, 1999Iip Inst Fuer Ind Pharmazie FoFeste Arzneimittelzusammensetzung auf der Grundlage von Selegilin
    DE-19743323-C2May 25, 2000Iip Inst Fuer Ind Pharmazie FoFeste Arzneimittelzusammensetzung auf der Grundlage von Selegilin
    EP-1637170-A1March 22, 2006Noven Pharmaceuticals, Inc.Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
    EP-1878420-A1January 16, 2008Japan Science and Technology Agency, Nanoegg Research Laboratories, Inc.Activateur de regeneration de la peau
    EP-1878420-A4August 12, 2009Japan Science & Tech Agency, Nanoegg Res Lab IncActivateur de regeneration de la peau
    EP-2258407-A2December 08, 2010Noven Pharmaceuticals, INC.Compositions transdermiques contenant des médicaments de faible poids moléculaire liquides à température ambiante
    EP-2371360-A3April 18, 2012Nitto Denko Corporation, Fujimoto Co., Ltd.Préparation adhésive contenant de la sélégiline
    US-5817336-AOctober 06, 1998Orion-Yhtyma OyComposition containing selegiline
    US-6033682-AMarch 07, 2000Somerset Pharmaceuticals, Inc.S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
    US-6210706-B1April 03, 2001Somerset Pharmaceuticals, Inc.S (+) Desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
    US-6242002-B1June 05, 2001Arzneimittelwerk Dresden GmbhEffervescent formulations
    US-6299901-B1October 09, 2001Somerset Pharmaceuticals, Inc.Methods and pharmaceutical compositions employing desmethylselegiline
    US-6316022-B1November 13, 2001Noven Pharmaceuticals, Inc.Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
    US-6319954-B1November 20, 2001Somerset Pharmaceuticals, Inc.S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
    US-6348208-B1February 19, 2002Somerset Pharmaceuticals, Inc.Methods and pharmaceutical compositions employing desmethylselegiline
    US-6375979-B2April 23, 2002Somerset Pharmaceuticals, Inc.S(+) desmethylselegiline and its use in transdermal delivery compositions
    US-6419948-B2July 16, 2002Somerset Pharmaceuticals, Inc.R(-)desmethylselegiline and its use in transdermal delivery compositions
    US-6420433-B2July 16, 2002Somerset Pharmaceuticals, Inc.S(+) desmethylselegiline and drug withdrawal
    US-6455060-B2September 24, 2002Somerset Pharmaceuticals, Inc.S(+) desmethylselegiline and its use to treat immune system dysfunction
    US-6461619-B1October 08, 2002Somerset Pharmaceuticals, Inc.Method for treating wounds, burns and dermatological damage by administering selegiline or desmethylselegiline
    US-6562364-B2May 13, 2003Somerset Pharmaceuticals, Inc.Desmethylselegiline enantiomers and their use to treat drug withdrawal symptoms
    US-6699495-B2March 02, 2004Somerset Pharmaceuticals, Inc.Methods for treating multiple sclerosis employing desmethylselegiline
    US-6759053-B2July 06, 2004Somerset Pharmaceuticals, Inc.S(+) Desmethylselegiline and its use to treat ADHD
    US-7070808-B2July 04, 2006Mylan Technologies, Inc.Adhesive mixture for transdermal delivery of highly plasticizing drugs
    US-7144584-B2December 05, 2006Somerset Pharmaceuticals, Inc.S(+) desmethylselegiline and its use to treat narcolepsy
    US-7150881-B2December 19, 2006Mylan Technologies, Inc.Adhesive mixture for transdermal delivery of highly plasticizing drugs
    US-7638140-B2December 29, 2009Mylan Technologies, Inc.Adhesive mixture for transdermal delivery of highly plasticizing drugs
    US-8093300-B2January 10, 2012Krele Pharmaceuticals, Inc.Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
    US-8337884-B2December 25, 2012Noven Pharmaceuticals, Inc.Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
    US-8481599-B2July 09, 2013Tonix Pharmaceuticals Inc.Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
    US-8846093-B2September 30, 2014Mylan Technologies, Inc.Adhesive mixture for transdermal delivery of highly plasticizing drugs
    WO-2005032514-A1April 14, 2005Richter Gedeon Vegyészeti Gyár Rt.Composition pharmaceutique transdermique
    WO-2008113565-A1September 25, 2008Universität TübingenFluorine-substituted amphetamines and amphetamine derivatives and use thereof